Clinical significance and different levels of urinary monocyte chemoattractant protein-1 in Type 2 diabetes mellitus

被引:22
|
作者
Qiu-Yue, Wang [1 ]
Fen-Qin, Chen [1 ]
机构
[1] China Med Univ, Affiliated Hosp 1, Dept Endocrinol, Shenyang 110001, Peoples R China
关键词
Diabetes mellitus; Diabetic nephropathy; Monocyte chemoattractant protein-1; KAPPA-B ACTIVATION; MYCOPHENOLATE-MOFETIL; NEPHROPATHY; SPIRONOLACTONE; ASSOCIATION; INJURY; MCP-1;
D O I
10.1016/j.diabres.2008.09.048
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: Monocyte chemoattractant protein-1(MCP-1) is a cytokine that exhibits most potent chemotactic activity toward monocytes. It is suggested to be implicated in the development and progression of diabetic nephropathy by playing a role in infiltration of monocyte/macrophage. Recent studies have demonstrated that urinary monocyte chemoattractant protein-1 (uMCP-1) is different at different stages of diabetic nephropathy. Based on these findings, the aim of this study is to examine the level of uMCP-1 and its clinical significance at different stages of diabetic nephropathy and at the same time to describe the relationship between uMCP-1 and the various parameters. Methods: Fifty-nine cases with type 2 diabetes mellitus (T2DM) were divided into three groups according to urine albumin excretion (UAE): normal albuminuria group, microalbuminuria group and macroalbuminuria group. The levels of uMCP-1, protein excretion, blood urea nitrogen (BUN), serum creatinine (s-Cr), glycohemoglobin A1c (HbA1c), blood pressure and blood fat were measured in 59 patients with T2DM and 27 healthy adults as controls. Results Compared with normal control, levels of uMCP-1 in T2DM were significantly high, which were already elevated in normal albuminuria group. Compared with normal albuminuria group, levels of uMCP-1 in microalbuminuria group and macroalbuminuria group were significantly high. Levels of uMCP-1 in macroalbuminuria group were higher than those in microalbuminuria group. The level of uMCP-1 was positively correlated with UAE, systolic blood pressure (SBP), diastolic blood pressure (DBP), total cholesterol (TC), low density lipoprotein cholesterol (LDL-C) in T2DM patients, while it had no significant correlation with HbA1c, triglyceride (TG) and high density lipoprotein cholesterol (HDL-C). Conclusions: MCP-1 is suggested to be implicated in the development and progression of diabetic nephropathy. it is very important to measure the level of uMCP-1 in the diagnosis and intervention of early diabetic nephropathy. (C) 2008 Elsevier Ireland Ltd. All rights reserved.
引用
收藏
页码:215 / 219
页数:5
相关论文
共 50 条
  • [31] Increase in circulating levels of monocyte chemoattractant protein-1 with aging
    Inadera, H
    Egashira, K
    Takemoto, M
    Ouchi, Y
    Matsushima, K
    JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 1999, 19 (10): : 1179 - 1182
  • [32] Monocyte chemoattractant protein-1 levels in patients with glomerular disease
    Rovin, BH
    Doe, N
    Tan, LC
    AMERICAN JOURNAL OF KIDNEY DISEASES, 1996, 27 (05) : 640 - 646
  • [33] Association between the A–2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus
    E. Simeoni
    M. M. Hoffmann
    B. R. Winkelmann
    J. Ruiz
    S. Fleury
    B. O. Boehm
    W. März
    G. Vassalli
    Diabetologia, 2004, 47 : 1574 - 1580
  • [34] Association between the A-2518G polymorphism in the monocyte chemoattractant protein-1 gene and insulin resistance and Type 2 diabetes mellitus
    Simeoni, E
    Hoffmann, MM
    Winkelmann, BR
    Ruiz, J
    Fleury, S
    Boehm, BO
    März, W
    Vassalli, G
    DIABETOLOGIA, 2004, 47 (09) : 1574 - 1580
  • [35] Monocyte chemoattractant protein-1 -2518 polymorphism is not associated with diabetic retinopathy in Japanese type 2 diabetes
    Yoshioka, Keiji
    Yoshida, Toshihide
    Kogure, Akinori
    Takakura, Yasuto
    Umekawae, Tsunekazu
    DIABETES & METABOLIC SYNDROME-CLINICAL RESEARCH & REVIEWS, 2009, 3 (03) : 166 - 168
  • [36] Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy
    Takebayashi, Kohzo
    Matsumoto, Sachiko
    Aso, Yoshimasa
    Inukai, Toshihiko
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2006, 91 (06): : 2214 - 2217
  • [37] Progression of Type 2 Diabetic Nephropathy and Serum Monocyte Chemoattractant Protein-1 (MCP-1) Levels
    Mohammed, Ahmed S.
    Al-Saeed, Hassan H.
    Malik, Arif Sami
    Alhassnawi, Muqdam Ali
    Khlaif, Mohammed S.
    Qassim, Ali Abdulla
    RESEARCH JOURNAL OF BIOTECHNOLOGY, 2023, 18 (09): : 132 - 136
  • [38] Induction of monocyte chemoattractant protein-1 in proximal tubule cells by urinary protein
    Wang, YP
    Chen, JC
    Chen, LG
    Tay, YC
    Rangan, GK
    Harris, DCH
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 1997, 8 (10): : 1537 - 1545
  • [39] Different roles of monocyte chemoattractant protein-1 in smokers and nonsmokers
    Shimada, S.
    Komiyama, M.
    Ono, K.
    Wada, H.
    Yamakage, H.
    Asahara, N.
    Akao, M.
    Morimoto, T.
    Takahashi, Y.
    Hasegawa, K.
    EUROPEAN HEART JOURNAL, 2016, 37 : 554 - 555
  • [40] Monocyte chemoattractant protein-1 and the kidney
    Haller, Hermann
    Bertram, Anna
    Nadrowitz, Felix
    Menne, Jan
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2016, 25 (01): : 42 - 49